Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B12-8D3
- Development stage
- Preclinical
- Lead developer
- Uppsala University
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
B12-8D3 is a bispecific antibody construct designed as a non-binding control for evaluating brain-shuttle technologies in central nervous system research. It is composed of the B12 monoclonal antibody, which targets HIV-1 gp120 and does not bind to endogenous brain antigens, fused to a single-chain Fab (scFab) fragment of the 8D3 antibody. The 8D3 component specifically targets the transferrin receptor protein-1 (TfR1), facilitating transport across the blood-brain barrier (BBB) via receptor-mediated transcytosis. In preclinical studies for Alzheimer's disease, B12-8D3 is often radiolabeled with isotopes such as Zirconium-89 (89Zr) for immuno-PET imaging. It serves as a critical baseline to isolate the effects of BBB shuttling from specific target engagement, allowing researchers to quantify non-specific brain uptake and distribution compared to therapeutic candidates like Adu-8D3.
- Other names
- [89Zr]Zr-DFO*-B12-8D3
02
Targets
Aβ (Amyloid-beta peptides and aggregates)TFRC (Transferrin Receptor)
Beyond the preview
Go deeper on B12-8D3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B12-8D3.